Brief: Olema Oncology Receives FDA Fast Track Designation For OP-1250 For The Treatment Of ER+ / HER2- Metastatic Breast Cancer
21/07/2022 12:47
July 21 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY RECEIVES FDA FAST TRACK DESIGNATION FOR
OP-1250
FOR THE TREATMENT OF ER+ / HER2- METASTATIC BREAST CANCER
Source text for Eikon: ID:nGNX2QtmPL
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs